Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The NIH website-transition announcement banner no longer appears above the 403 error page.
    Difference
    1%
    Check dated 2026-11-09T13:24:51.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.2 to v3.8.0, while the page still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T13:22:39.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH website transition updates and says federal agencies are shifting terminology from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T15:22:09.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T15:59:56.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-12T15:58:52.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    The study record page displays a 403 Forbidden message and a Home link instead of the record content.
    Difference
    0.5%
    Check dated 2026-10-05T18:20:53.000Z thumbnail image

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.